

Integrating General Health Care in Private Community Psychiatry Practice

Donald C. Goff, M.D.

Persons with serious mental illness represent a special at-risk population, with elevated medical comorbidity and mortality rates, mainly due to cardiovascular disease. For this reason, the treatment plan for patients with mental illness must include the assessment of medical risk factors, beginning at the time of the initial psychiatric evaluation. Follow-up assessments should proceed as recommended by the Expert Consensus Development Panel convened by the American Diabetes Association, the American Psychiatric Association, and other relevant specialty organizations. Because the various second-generation antipsychotics (SGAs) have unique side effect profiles with respect to cardiometabolic risk factors, such as weight gain and dyslipidemia, the selection of an SGA always should weigh efficacy versus potential risks. Prior to initiating antipsychotic therapy, the psychiatrist should not only explain to the patient the risks of the medication and alternative treatments, but also address preventive strategies and the importance of monitoring. To help evaluate the patient's response and manage SGA-related adverse effects, the psychiatrist should spend considerable time in contact with the patient, the patient's family and/or caregivers (as appropriate), and the patient's primary care physician. To enhance overall patient care, the psychiatrist in private practice should implement procedures to ensure adequate patient education and address overall health monitoring. Furthermore, the psychiatrist must serve as a patient advocate, actively working to foster communication with medical colleagues, especially primary care practitioners, and identify resources in the community that facilitate preventive health care.

(J Clin Psychiatry 2007;68[suppl 4]:49-54)

The psychiatrist in private practice can face considerable challenges when integrating medical and psychiatric care. Obstacles often include time constraints, as well as an absence of ancillary personnel to assume responsibility for health education, monitoring, and outreach. In addition, if the solo practitioner is not part of a larger health care system, integration of medical and psychiatric care may be even more difficult. As a result, the psychiatrist in private practice must assume a variety of roles. In addition to patient education and monitoring, this includes actively working to foster communication with medical colleagues and identifying resources in the community that can facilitate preventive health care.

In formulating a strategy to integrate medical and psychiatric care, the solo practitioner must first become familiar with the multiple health care needs that characterize the chronically mentally ill. Patients with mental illness have a higher relative risk of death than the general population.^{1,2} Moreover, death often occurs at a younger age among the mentally ill,^{1,2} with the life expectancy shortened by as much as 20% in persons with schizophrenia.² The excess mortality rate among the mentally ill has been attributed to "natural causes" and preventable medical ill-

nesses, such as heart disease, cancer, cerebrovascular disease, and pulmonary illnesses, with heart disease being the leading cause of death.¹ In addition, among all patients with mental illness, those with more severe and chronic symptoms tend to have less access to appropriate medical care and are more likely to suffer iatrogenic metabolic disturbances resulting from pharmacotherapy.

CAUSES OF EXCESS MORTALITY AND MORBIDITY

Several recent publications³⁻⁵ have reviewed a number of factors that contribute to the excess morbidity and mortality in patients with schizophrenia, including poor nutrition, cigarette smoking, other substance abuse, sedentary lifestyle, obesity, infectious diseases (including hepatitis and HIV), and metabolic consequences of medications. A recent study⁶ of a representative national sample of patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) found that the estimated 10-year risk of cardiac disease was significantly elevated compared with matched controls from the general population. The increased risk among schizophrenia patients resulted from higher rates of cigarette smoking (68% vs. 35%, $p = .0001$), diabetes (13% vs. 3%, $p = .0001$), and hypertension (27% vs. 17%, $p = .0001$), as well as dyslipidemia. In the same sample, rates of metabolic syndrome, a serious cardiac risk factor believed to represent the consequences of insulin resistance, were increased by 138% in men and by 251% in women with schizophrenia.⁷ Cardiac risk appears to be even greater in patients treated with certain second-generation antipsychotics (SGAs). For example, in a 10-year naturalistic study of patients treated with clozapine,⁸ the 10-year mortality rate from cardiac disease was 9% and the rate of new-onset diabetes was 43%—both rates are alarmingly high compared with rates in other populations. In particular, blacks and Hispanics were at increased risk for diabetes, as were obese patients.

While attention has focused increasingly on the high rates of cardiac disease in patients with schizophrenia, the greater vulnerability to infectious diseases also should be emphasized. Sur-

From the Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.

This article was derived from the editorial planning roundtable "Strategies to Integrate Physical Health Care Into Mental Health," which was held August 28, 2006, in Philadelphia, Pa., and supported by an educational grant from Bristol-Myers Squibb Co., Princeton, N.J., and Otsuka America Pharmaceutical, Inc., Rockville, Md.

Dr. Goff has received grant/research support from Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Janssen, and Pfizer; has received honoraria from Bristol-Myers Squibb, Eli Lilly, Janssen, and Pfizer; has served on the advisory boards of AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Merck, and Pfizer; and has served on a data and safety monitoring board for Wyeth.

Corresponding author and reprints: Donald C. Goff, M.D., Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St., 2nd Floor, Boston, MA 02114 (e-mail: goff@psych.mgh.harvard.edu).

veys^{4,9} have found a 5- to 10-fold increase in rates of HIV and hepatitis B and C infections in the chronically mentally ill. These individuals also are at greater risk for pulmonary disease, particularly pneumonia and emphysema, although lung cancer does not appear to be as prevalent as might be predicted by the high rates of cigarette smoking, possibly reflecting a protective genetic factor.¹⁰ Substance abuse, which is common yet often undetected in psychiatric patients, threatens patient health via many routes, including intravenous infection, overdose, intoxication-related injuries, compromised nutrition, and health risks taken in the process of procuring drugs.

ASSESSING AND ADDRESSING MEDICAL RISK FACTORS

To minimize and prevent excess medical comorbidity and mortality, the assessment of medical risk factors should be incorporated into the initial psychiatric evaluation (Table 1). Due to the high prevalence of cardiovascular morbidity and mortality, the psychiatrist should be conversant with cardiovascular risk factors and the goals of treatment to help reduce or eliminate these risk factors (Tables 2–4). In addition to a standard medical history and review of systems, the psychiatrist should inquire about family medical history, cigarette smoking, substance abuse, high-risk behaviors (including unprotected sexual activity), nutritional status, exercise, and medical care (including compliance with regular medical examinations and treatments).

The process of patient education can start at the first visit by conveying the seriousness of potential health risks and the importance of preventive health measures. This information should be communicated to the patient and, if appropriate, family members and other caregivers. In some settings, a nurse or other member of a multidisciplinary team can take a lead role in patient education. In addition, providing printed educational materials or the use of educational videos may be helpful. Topics discussed with the patient should include nutrition, exercise, infectious disease precautions (including “safe sex”), health consequences of cigarette smoking and other substance abuse, weight reduction, and the importance of compliance with routine medical screening and treatments.

Although a psychiatric clinician in solo private practice is unlikely to possess the expertise or resources necessary to provide interventions for the full range of medical risk factors, the psychiatrist should be able to identify programs in the community that offer nutritional counseling, supervised exercise programs, smoking cessation programs, and dual-diagnosis treatment. Despite frequent pessimism on the part of physicians and patients, recent studies⁴ have suggested that weight reduction and smoking cessation are realistic goals that can be achieved with approaches specifically designed for individuals with chronic mental illness. Nutritional counseling and exercise programs should be designed and modified as necessary to accommodate the needs of psychiatric patients who may require a more simplified approach, with repetition of educational lessons, extra staff support, the use of food diaries, and the expectation that several attempts may be necessary before the patient is successful.⁴ Education and behavioral/lifestyle interventions targeted to mental health patients are discussed in detail by Dr. Ganguli²⁰ and Ms. Vreeland²¹ in their respective articles in this supplement.

For smoking cessation, bupropion and nicotine replacement therapy have been found to improve success rates in patients

with schizophrenia when combined with cognitive-behavioral approaches.^{4,22–24} Bupropion also may prevent symptomatic worsening associated with nicotine withdrawal.²³ Continued use of bupropion or nicotine replacement therapy may be necessary to maintain smoking cessation in patients with schizophrenia, in contrast to the time-limited approach taken by traditional smoking cessation programs.⁴

MANAGING SGA-RELATED METABOLIC DISTURBANCES

The initial selection of an SGA should involve a careful weighing of its efficacy against potential cardiometabolic risks. For guidance, the clinician should refer to the joint statement from the American Diabetes Association (ADA)/American Psychiatric Association (APA) Consensus Development Panel composed of experts from these and other relevant specialty organizations, who reviewed the evidence on metabolic side effects associated with antipsychotic agents.³ The panel concluded that olanzapine and clozapine produced the greatest weight gain and were most clearly linked to the risk of diabetes mellitus and dyslipidemia. Risperidone and quetiapine were found to produce intermediate weight gain, and the evidence linking these agents to diabetes and dyslipidemia was judged to be “discrepant” or uncertain. Ziprasidone and aripiprazole were associated with the least weight gain, and the panel concluded that the available data did not support a relationship between the use of these agents and an increased risk of diabetes or dyslipidemia. Consistent with the panel’s recommendation, the National Institute of Mental Health–initiated CATIE study²⁵ also observed that olanzapine was associated with significantly greater weight gain ($p < .001$) and elevations of glycosylated hemoglobin ($p < .01$), triglycerides ($p < .001$), and total cholesterol ($p < .001$) than other SGAs.

When prescribing psychotropic medication with potential adverse medical effects, the psychiatrist carefully should explain to the patient the risks of the medication and the alternative treatments, as well as preventive strategies and the importance of monitoring. It is clear that when the patient is involved in the process of selecting a medication on the basis of such pretreatment education, the emergence of adverse effects is less likely to jeopardize adherence and the treatment alliance. The psychiatrist should spend considerable time with the patient, the patient’s family members (when possible and appropriate), and the primary care physician to help evaluate the patient’s response and manage treatment-emergent adverse effects. Further, because both effectiveness and metabolic side effects vary considerably between patients and cannot be predicted, the selection of the optimal agent for an individual patient may require several trials. This process should involve the patient and, when possible, family members and the primary care physician.

Once the decision to initiate antipsychotic treatment is made, the ADA/APA Consensus Development Panel’s schedule for monitoring metabolic effects should be followed.³ Prior to initiation of SGA treatment, a careful assessment should be made of cardiac risk factors, including family history and the measurement of weight, body mass index (BMI), waist circumference, blood pressure, fasting glucose concentration, and lipid levels. Thereafter, weight should be recorded every 4 weeks for the first 3 months, then quarterly, while waist circumference, blood pressure, fasting blood sugar, and a lipid panel should be repeated after 4 months, then annually. The frequency of assessments should

Table 1. Guidelines for the Integration of Medical Care^a

Initial evaluation	Special circumstances
Perform a complete medical history, substance abuse history, family medical history, and review of systems	Overweight patients: BMI ≥ 25 in women or ≥ 30 in men and 2 obesity-related risk factors OR waist circumference ≥ 88 cm (≥ 35 in) in women or ≥ 102 cm (≥ 40 in) in men and 2 obesity-related risk factors
Record weight, waist circumference, height, blood pressure, and pulse; calculate BMI; and assess activity level	Refer for nutritional counseling and exercise program
Ask specific questions about risk behaviors, including the risk of viral transmission, time spent in institutions, exposure to domestic or partner violence, use of seatbelts and bike helmets, smoking, and substance use	Weight reduction programs should last ≥ 6 mo and be followed up continuously
Establish communication with the patient's primary care physician and any other relevant medical care providers; if the patient is not receiving consistent medical care, a referral should be made and facilitated, as necessary	Consider a switch to a weight-neutral antipsychotic agent (ziprasidone, aripiprazole, molindone) ^b
Obtain the results of the most recent physical examination, laboratory, electrocardiogram, and other relevant tests; if not completed within the previous 6 mo, arrange an appropriate medical evaluation	Abnormal fasting glucose (see Table 2 for diagnostic thresholds and goals)
Assess the patient's level of knowledge regarding health factors (weight, diet, exercise, smoking, high-risk sexual behaviors, and substance abuse) and receptiveness to change and provide psychoeducational resources, as appropriate; also, communicate general information on primary prevention of disease	Refer for nutritional counseling and exercise program after medical clearance
	Refer for medical assessment
	Educate patient and family members about warning signs of uncontrolled diabetes (polyuria, polydipsia, and weight loss)
	Consider a switch from clozapine or olanzapine to alternative agents ^b
Every visit	Smoking
Review all new somatic symptoms and changes in medication prescribed by other caregivers	Assess receptiveness to smoking cessation
Monitor compliance with medical treatment	Offer advice and encouragement to stop smoking
Determine possible exposure to infectious disease, particularly unsafe sexual behaviors and parenteral drug use	Refer for smoking cessation program, offering behavioral interventions and NRT or bupropion
Explore and encourage receptiveness to smoking cessation if currently smoking	Maintain frequent contact during patient's attempts to stop smoking; monitor for signs of increased medication levels in response to smoking cessation
Review the use of illicit drugs and alcohol and offer treatment, as appropriate	Encourage repeated attempts to quit in the face of failures
Semiannually (every 6 mo)	Hypertension (see Table 3 for blood pressure goals)
Communicate with primary care physician	Refer for nutritional counseling and exercise program after medical clearance
Assure that weight, height, and BMI have been recorded in the last 6 mo (if an SGA has been started recently, weight should be recorded every 4 wk for 12 wk, then quarterly)	Review salt, alcohol, and overall diet, particularly intake of fruit and vegetables
Review psychoeducational needs and refer to nutritional counseling, smoking cessation program, exercise program, safe-sex education, and substance abuse treatment, as appropriate	Encourage smoking cessation program if a smoker
Annually	Refer for medical evaluation and treatment
Assure that fasting glucose and blood pressure have been measured annually (if an SGA has been started recently, blood pressure and fasting glucose should be measured after 12 wk)	Hyperlipidemia (see Table 4 for cholesterol goals)
Confirm that all necessary screening studies have been completed, including mammography, pap smear, and colonoscopy, as appropriate; psychiatric interventions for anxiety or paranoia may be needed to facilitate completion of these tests	Refer for nutritional counseling and exercise program after medical clearance
Measure lipids annually in patients with a higher risk for coronary heart disease (ie, diabetes, multiple cardiovascular risk factors including older age, smoking, elevated blood pressure, and other metabolic risk factors)	Assure yearly measurement of fasting serum lipids
Review immunization status (PPD, hepatitis B, pneumococcal, and tetanus)	Refer for medical evaluation and treatment
Review residential safety, including smoke detectors and removal of firearms	Consider switching to another antipsychotic medication if treated with clozapine or olanzapine ^b
Discuss health habits, including exercise and use of seatbelts and bicycle helmets	High-risk behaviors for HIV or hepatitis
Formulate goals with patient for health enhancement and primary prevention	Refer for intensive behavioral education program
	Refer for counseling and HIV and hepatitis screening, as appropriate
	Starting an SGA
	Record weight, BMI, waist circumference, blood pressure, fasting glucose, and fasting lipid profile at baseline
	Repeat weight at 4 wk for 12 wk, then quarterly
	Repeat waist circumference annually
	Repeat blood pressure and fasting glucose at 12 wk, then annually
	Repeat lipid profile at 12 wk, then every year in patients with elevated coronary heart disease risk
	Consider switching medication if the patient gains $\geq 5\%$ of his or her initial weight, BMI increases by 1 unit, waist circumference is ≥ 88 cm (≥ 35 in) in women or ≥ 102 cm (≥ 40 in) in men, or if elevated fasting glucose or undesirable lipid levels develop ^b

^aAdapted with permission from Goff et al.⁴ Based on references 2, 5, and 11–19.

^bIn stable patients, medication switches should only be considered if other interventions fail to reduce medical risk. The effectiveness of the current medication must be carefully weighed against the relative risks of medical morbidity, particularly in patients with a history of suicidality, who have responded preferentially to the current medication. Risk of weight gain is greatest with clozapine and olanzapine, intermediate with risperidone and quetiapine, and least with aripiprazole and ziprasidone.³ Dyslipidemia and diabetes are most strongly associated with clozapine and olanzapine; an association with risperidone and quetiapine is uncertain; and limited data have not indicated an association with aripiprazole or ziprasidone.³ Abbreviations: BMI = body mass index, NRT = nicotine replacement therapy, PPD = tuberculin skin testing, SGA = second-generation antipsychotic.

Table 2. Diagnostic Thresholds for Diabetes and Impaired Fasting Glucose^a

Fasting Plasma Glucose (FG)	Interpretation According to the American Diabetes Association	Treatment Goals and Recommended Intervention
< 100 mg/dL	FG upper limit of normal	Interventions Weight loss Appropriate nutrition Increased physical activity Close monitoring and follow-up counseling Monitor and treat cardiovascular risk factors FG goal (intensive glycemic control) Preprandial glucose: 90–135 mg/dL Postprandial glucose: < 180 mg/dL HbA _{1c} : < 7% All interventions listed for prediabetes + oral hypoglycemics or insulin injections Medical nutrition therapy Prevent and manage diabetic complications
100–125 mg/dL	Impaired FG/prediabetes	
≥ 126 mg/dL	Diagnostic for diabetes (confirmed on a subsequent day)	

^aBased on American Diabetes Association.¹⁹
 Abbreviation: HbA_{1c} = glycosylated hemoglobin.

Table 3. Adult Treatment Panel III (ATP III) Cholesterol Goals and Thresholds for Lifestyle Changes and Drug Therapy^a

Risk Category	LDL-C Goal	Initiate Therapeutic Lifestyle Changes	Consider Drug Therapy
CHD or CHD risk equivalents ^b (10-y risk >20%)	< 100 mg/dL (optional goal: < 70 mg/dL)	≥ 100 mg/dL ^c	≥ 100 mg/dL (< 100 mg/dL: consider drug therapy) ^c
2+ risk factors ^d (10-y risk 10%–20%)	< 130 mg/dL (optional goal: < 100 mg/dL)	≥ 130 mg/dL	≥ 130 mg/dL (100–129 mg/dL: consider drug therapy) ^c
2+ risk factors ^d (10-y risk <10%)	< 130 mg/dL	≥ 130 mg/dL	≥ 160 mg/dL
0 or 1 risk factor	< 160 mg/dL	≥ 160 mg/dL	≥ 190 mg/dL (160–189 mg/dL: LDL-C–lowering drug optional)

^aBased on National Heart, Lung, and Blood Institute.¹⁸

^bCoronary heart disease (CHD) risk equivalent includes the presence of peripheral arterial disease, carotid artery disease, abdominal aortic aneurysm, diabetes, and 2+ risk factors, with a 10-year risk for CHD of > 20%.

^cPatients who have lifestyle-related risk factors are candidates for therapeutic lifestyle changes to modify these risk factors, regardless of low-density lipoprotein cholesterol (LDL-C) level.

^dMajor risk factors, exclusive of LDL-C, that modify LDL-C goals include cigarette smoking, hypertension or taking antihypertensive medication, low high-density lipoprotein cholesterol, family history of premature CHD, and age (men ≥ 45 years; women ≥ 55 years).

^eInitiation of LDL-C–lowering drug is a therapeutic option on the basis of available clinical trial results.

reflect the patient’s risk factors, as well as the relative metabolic risk of the SGA. More frequent monitoring may be appropriate for higher-risk situations.³

In addition, the psychiatrist in private practice should inform the patient’s primary care provider of the need to monitor metabolic parameters. Although the primary care physician will perform some or all of the medical monitoring, the psychiatrist should coordinate the overall monitoring process. Similarly, if metabolic abnormalities arise, the psychiatrist can enlist the primary care physician’s help in managing these side effects, including referral for behavioral interventions. Some practitioners may be wary of approaching the primary care physician because of Health Insurance Portability and Accountability Act (HIPAA)–related privacy issues. However, it should be emphasized that, according to the U.S. Department of Health and Human Services,²⁶ the HIPAA privacy rule “does not restrict the ability of doctors, nurses, and other providers to share information needed to treat their patients,” although care must be taken to share “only the minimum amount of protected information needed for a particular purpose.”

Interventions, including the consideration of a change in antipsychotic medication, should be recommended if the patient gains greater than 5% of his or her body weight, if the BMI increases by 1 unit, or if the waist circumference is greater than or

equal to 88 cm (≥ 35 in) in a female patient or greater than or equal to 102 cm (≥ 40 in) in a male patient.^{3–5} For adverse effects, such as weight gain or dyslipidemia, or for enhanced glycemic control, the management strategy should always involve educational and behavioral interventions, which are discussed in detail by Dr. Ganguli²⁰ and Ms. Vreeland²¹ in their respective articles in this supplement. If interventions are not effective, a switch to a more metabolically neutral antipsychotic agent should be considered. Considerations for switching are described in detail by Dr. Weiden²⁷ in another article in this supplement.

PSYCHIATRIST AS PATIENT ADVOCATE

In many cases, the severely mentally ill may be unable to describe somatic complaints to their primary care physician or, because of their psychiatric diagnosis, the veracity of these complaints may be questioned by the primary care physician. In addition, psychiatric patients may find it difficult to navigate fragmented care systems, and their psychiatric illness may interfere with compliance in medical screening and treatment. Several studies^{28,29} have found that psychiatric patients, particularly those with schizophrenia, receive inferior care and experience poorer medical outcomes compared with other medical patients, either as the result of stigma or poor compliance. Thus, in addition to providing information about psychotropic medications to pri-

Table 4. Seventh Report of the Joint National Committee (JNC 7) Recommendations for Management of Blood Pressure^a

Blood Pressure Classification	Systolic Blood Pressure ^b (mm Hg)	and	Diastolic Blood Pressure ^b (mm Hg)	Lifestyle Modification	Initial Drug Therapy	
					Without Compelling Indication	With Compelling Indication ^c
Normal	< 120	and	< 80	Encourage	No antihypertensive drug indicated	Drugs for compelling indications ^d
Prehypertension	120–139	or	80–89	Yes		
Stage 1 hypertension	140–159	or	90–99	Yes	Thiazide-type diuretics for most; may consider ACEI, ARB, BB, CCB, or combination	Drug(s) for the compelling indications ^d ; other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed
Stage 2 hypertension	≥ 160	or	≥ 100	Yes	2-drug combination for most ^e (usually thiazide-type diuretic and ACEI or ARB or BB or CCB)	

^aBased on National Heart, Lung, and Blood Institute.¹⁷

^bTreatment determined by highest blood pressure category.

^cCompelling indications for drug therapy include heart failure; postmyocardial infarction; high risk for coronary disease, diabetes, and chronic kidney disease; and recurrent stroke prevention. Refer to guidelines for recommended drugs from compelling indications.

^dTreat patients with chronic kidney disease or diabetes to blood pressure goal of < 130/80 mm Hg.

^eInitial combined therapy should be used cautiously in those at risk for orthostatic hypotension.

Abbreviations: ACEI = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, BB = β -blocker, CCB = calcium channel blocker.

mary care physicians and sharing monitoring responsibilities, it is critical that the psychiatrist in private practice be prepared to advocate for patients when necessary to ensure adequate medical care. This process of patient advocacy should begin at the first visit by obtaining the necessary consent to contact the patient's primary care physician, followed by regular communication between the psychiatrist and the primary care physician. It should be noted that, while patient consent is appropriate and contributes to the therapeutic alliance, it is not absolutely required under HIPAA for health care professionals to share information for the coordination of patient care.²⁶ Although the psychiatrist in private practice is often limited by time constraints and may not have a nurse or other staff to assist patients in their interactions with the medical system, regular communication between the psychiatrist and primary care physician can have a very positive impact on the process.³⁰

CONCLUSION

Just as medical health and physical health are intertwined,¹ so must the efforts of the psychiatrist and the primary care physician be combined to address the full spectrum of health needs of the psychiatric patient. Individuals with chronic psychiatric illness represent a special at-risk population with unique medical needs. Hence, the treating psychiatrist must assume a leadership role in providing health care that addresses the patient's medical as well as psychiatric problems. To do this will require efforts that expand the solo practitioner's focus beyond the traditional office setting to include contact with primary care physicians and various community resources. When these efforts are made, despite the inherent time and personnel constraints of solo practice, the anticipated result is enhanced overall patient health and improved medical and psychiatric outcomes.

Drug names: aripiprazole (Abilify), bupropion (Zyban and others), clozapine (FazaClo, Clozaril, and others), molidone (Moban), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), ziprasidone (Geodon).

Disclosure of off-label usage: The author has determined that, to the best of his knowledge, no investigational information about pharmaceutical agents that is outside U.S. Food and Drug Administration–approved labeling has been presented in this article.

REFERENCES

- Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. *Prev Chronic Dis* [serial online] 2006 April. Available at: http://www.cdc.gov/pcd/issues/2006/apr/05_0180.htm. Accessed Oct 15, 2006
- Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. *Am Heart J* 2005;150:1115–1121
- American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. *J Clin Psychiatry* 2004;65:267–272
- Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. *J Clin Psychiatry* 2005;66:183–194
- Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry* 2004;161:1334–1349
- Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. *Schizophr Res* 2005;80:45–53
- McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. *Schizophr Res* 2005;80:19–32
- Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. *J Clin Psychiatry* 2005;66:1116–1121
- Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. *Am J Public Health* 2001;91:31–37
- Lichtermann D, Ekelund J, Pukkala E, et al. Incidence of cancer among patients with schizophrenia and their relatives. *Arch Gen Psychiatry* 2001;58:573–578
- Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the evidence report. National Institutes of Health. *Obes Res* 1998;6(suppl 2):51S–209S
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486–2497
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2003;26(suppl 1):S5–S20
- Franz MJ, Bantle JP, Beebe CA, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. *Diabetes Care* 2003;26(suppl 1):S51–S61
- American Diabetes Association. Standards of medical care for patients with

- diabetes mellitus. *Diabetes Care* 2003;26:S33–S50
16. Fiore M. A clinical practice guideline for treating tobacco use and dependence: a US public health service report. *JAMA* 2000;283:3244–3254
 17. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Available at: <http://www.nhlbi.nih.gov/guidelines/hypertension/index.htm>. Accessed Feb 22, 2007
 18. National Heart, Lung, and Blood Institute. National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Available at: <http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04.htm>. Accessed Feb 22, 2007
 19. American Diabetes Association. Standards of medical care in diabetes: 2006. *Diabetes Care* 2006;29(suppl 1):S4–S42
 20. Ganguli R. Behavioral therapy for weight loss in patients with schizophrenia. *J Clin Psychiatry* 2007;68(suppl 4):19–25
 21. Vreeland B. Bridging the gap between mental and physical health: a multidisciplinary approach. *J Clin Psychiatry* 2007;68(suppl 4):26–33
 22. Evins AE, Mays V, Cather C, et al. A placebo controlled trial of sustained release bupropion added to cognitive behavioral group therapy for smoking cessation in schizophrenia. *Nicotine Tob Res* 2001;3:397–403
 23. Evins AE, Deckersbach T, Cather C, et al. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. *J Clin Psychiatry* 2005;66:1184–1190
 24. Evins AE, Cather C, Rigotti NA, et al. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. *J Clin Psychiatry* 2004;65:307–311
 25. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005;353:1209–1223
 26. US Department of Health and Human Services. Protecting the privacy of patients' health information. April 14, 2003. Available at: <http://www.hhs.gov/news/facts/privacy.html>. Accessed Oct 13, 2006
 27. Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. *J Clin Psychiatry* 2007;68(suppl 4):34–39
 28. Druss BG, Bradford DW, Rosenheck RA, et al. Mental disorders and use of cardiovascular procedures after myocardial infarction. *JAMA* 2000;283:506–511
 29. Druss BG, Bradford WD, Rosenheck RA, et al. Quality of medical care and excess mortality in older patients with mental disorders. *Arch Gen Psychiatry* 2001;58:565–572
 30. Druss BG, Rohrbaugh RM, Levinson CM, et al. Integrated medical care for patients with serious psychiatric illness: a randomized trial. *Arch Gen Psychiatry* 2001;58:861–868